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ABSTRACT
Detection and profiling of circulating tumor cells (CTCs) is useful for cancer
screening and for managing treatment of carcinoma patients. Label-free technologies aim
to accomplish detection rapidly with small, simple micro and nano devices. Carbon
nanotubes are favorable molecular sensors due to their unique properties. They have been
widely investigated for immunosensing of cancer biomarkers as free proteins, but very
little has been done to detect biomarkers in intact cells and much remains to be
understood regarding the mechanism of their sensing.
We have developed a simple carbon nanotube biosensor for epithelial cell
adhesion molecule (EpCAM) for sensing EpCAM positive cells. Sensor fabrication steps
involving minimal air exposure were employed which reduced random noise upon
sample introduction to the device. Optimized sensors recognized specific interactions
with EpCAM positive MCF-7 cells and did not recognize EpCAM negative MCF-10A
cells, producing the same characteristic signal as for blank phosphate buffered saline
samples (no interaction). A two sample t-test found that the specific and nonspecific
signals were significantly different, p = 0.0235. Specific binding signals are attributed to
the combined binding events and negative cell membrane potential.
.
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I.

INTRODUCTION

Cancer is the second leading cause of death in the United States, totaling 567,628
deaths in 2009, the most recent complete data (Heart disease is the first with 599,413)[1].
Cancer cells originate from the body’s own tissue and thus are difficult to distinguish
from healthy cells, even undetectable by the body’s own immune system. This presents a
challenge for cancer diagnosis and therapy -- to identify malignant cells among normal
ones, and to treat them with chemotherapeutics and other agents while preserving healthy
tissue.
There are ways in which malignant cells belie their true nature however. They
express certain surface markers, proteins embedded in the cellular membrane, at much
higher levels than normal tissue. Much research has been done to identify these surface
proteins, deemed cancer biomarkers, and correlate them to specific cancer types. To
translate this knowledge into clinical utility, reliable and efficient testing methods are
needed. Testing for cancer biomarkers can be used for cancer screening and for
monitoring confirmed cancer cases.
Tumor biopsies are the most direct route to obtain samples for biomarker testing
but their invasive nature is detrimental to the patient, and limits the number of tests which
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can be done. Also for the purposes of screening, tumors must be detected by some other
method before undergoing further tests.
Circulating tumor cells (CTC) are tumor cells which have escaped into the
bloodstream and display the same biomarkers. CTCs were first documented in 1869 by
Australian physician Thomas Ashworth, who identified cancer cells in the blood sample
of a metastatic cancer patient by observing their morphology in a light microscope[2],
[3]. Ashworth correctly predicted that CTCs were responsible for the spread of the
cancer, but not until the recent identification of cancer biomarkers and development of
molecular recognition technologies has their diagnostic potential been explored.
CTCs are present at concentrations of 50-300,000 cells/µL in metastatic cancer
patients[4]. CTCs represent a less invasive sampling option and are systemic indicators
rather than from one local tumor site [5]. The number of CTCs counted, and/or the
biomarkers they display are strong indicators of patient prognosis[2], [6], [7], helpful in
determining the efficacy of adjuvant therapies[4] and can even tell physicians whether
certain treatments will be effective. For example Herceptin, a therapeutic agent which
targets breast cancer biomarker Her2 antigen, is effective for Her2 + and ineffective for
Her2 – cancers[8]. Taking cancer type into account, certain biomarkers indicate the
patients prognosis and this information can be used to spare patients with positive
prognoses from unnecessary chemotherapy[9].
In 2008, the Veridex CellSearch system became the first FDA approved method
for CTC detection[10], [11]. The system takes a 7.5 mL blood sample and tags CTC with
magnetic nanoparticles, and a fluorescent dye specific to epithelial cells. A magnetic field
2

pulls tagged cells to the surface of a sorting chamber. Then a fluorescent optical scan
verifies which cells are CTCs and counts their number[2], [12]. The CellSearch system
detects 85% of CTCs in a sample with 95% confidence, thus its detection limit is 1.2+/0.4 CTCs per 7.5 mL sample[13]. The CellSearch technology is also being used as a
research tool to gain new understanding of the metastatic process[14].
Its accuracy makes CellSearch a strong clinical tool but it is ultimately dependent
on fluorescent molecular labeling and imaging in order to detect the CTCs. Therefore, it
requires large sophisticated equipment. Likewise, the bulk of detection methods in
current molecular biology practice utilize a labeling step and subsequent optical imaging
step to detect target molecules. The label is a molecule, tagged with a dye or other
indicator, which specifically binds to a target molecule. Antibodies, aptamers,
complementary DNA and other molecules can be used to bind specifically to targets.
Fluorescent dyes, enzymes, quantum dots, and other indicators can all be used as
tags[15]. These labeling schemes typically require extensive sample preparation and
sophisticated optical imaging devices.
Label-free techniques are being developed in an attempt to achieve the high
accuracy of standard molecular labeling at lower cost and complexity, thus improving the
accessibility of biomolecular information. This enables doctors to more effectively treat
their patients in the clinic, and researchers to acquire more complete knowledge in the
laboratory.
Label-free detection typically requires biomolecular interactions to be transduced
into electrical or mechanical signals. Carbon nanotubes are ideal biomolecular
3

transduction elements. Many properties of single-wall carbon nanotubes (SWNT) make
them desirable for these applications. Consisting of just a single carbon layer, their
diameter (~1 nm) is on the same order of size as many biomolecules, and every atom is
on the surface, exposed to the surrounding environment. They can be several microns or
even on the order of centimeters in length, which permits them to transmit signals over
relatively large distances.
Antibodies specific to cancer biomarkers, or other molecules of interest, can be
conjugated to the carbon nanotube sidewalls. Specific binding of the target molecule to
these conjugated antibodies alters the electrical response of the carbon nanotube,
presumably due to charge transfer and capacitive coupling. This can be readily observed
and has been demonstrated for free proteins, DNA, metabolites and others, but reports of
cellular sensing with these devices have not yet emerged in great number.
The promise of biosensing with carbon nanotubes entails low cost devices which
can rapidly detect multiple biomarkers via electrical signals, without the need for
complex equipment and procedures. Our present challenge is to understand and
characterize the electrical signals for immunosensing of cancer biomarkers on intact cells.
Contained in this thesis is a description of unique specific signatures for MCF7 mammary
adenocarcinoma cells which overexpress EpCAM.
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II.

A.

BACKGROUND

Epithelial Cell Adhesion Molecule, Cancer Biomarker

Specific recognition of Epithelial Cell Adhesion Molecule (EpCAM) in epithelial
cells is the focus of this study. EpCAM was chosen as a model system because it is
present in nearly all adenocarcinomas and squamous cell carcinomas[16]. In fact it is so
ubiquitously present in CTCs that the aforementioned CellSearch system exclusively uses
anti-EpCAM-magnetic nanoparticle conjugates to sort CTCs from blood samples[13].
EpCAM was first identified by the production of an antibody, designated 17-1A,
from mice immunized with human colorectal carcinoma derived cells[17]. 17-1A was
found to bind specifically to colorectal carcinoma cells, but not normal colon tissue, nor
to other malignant cell types such as melanomas, astrocytomas and fibrosarcomas.
EpCAM functions in mediating homophilic cell-cell adhesion, hence its name.
EpCAM is a 314 amino-acid tetrameric polypeptide with a 242 amino-acid extracellular
domain. It is only present in epithelial cells. The extracellular domain contains epidermalgrowth-factor-like domain and a thyroglobulin (TY) domain. A 26 amino acid
cytoplasmic domain associates with the actin filaments of the cytoskeleton[16].
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Figure II.1 Revised EpCAM structural model, from [16]

EpCAM’s role in cancer is a complicated one. By forming cell-cell adhesions,
EpCAM inhibits metastasis when transfected into tumor cells in mice. However EpCAM
adhesions are weaker than common cell-cell adhesions such as cadherins, and increased
EpCAM expression is correlated with decreased cadherin expression. So by replacing
strong cell-cell adhesions with weaker ones, EpCAM could facilitate metastasis. Thus for
some cancers (breast, ovarian and others) EpCAM expression has a negative influence on
patient survival, but for other cancers (gastric, renal and others) EpCAM expression has a
positive influence on patient survival[16], [18]. The 17-1A antibody was investigated as a
therapeutic agent itself and adjuvant therapy of colorectal cancer patients successfully
reduced their 7 year mortality, but it was ineffective against large solid tumors[18].
In either case, EpCAM expression correlates with increased proliferation and dedifferentiation of cells. EpCAM mediates a signaling pathway which can be triggered
through zones of cell-cell contact. When triggered, EpCAM is cleaved by proteases and
an intracellular peptide termed EpIC is released. Intracellular receptors for EpIC initiate
6

the formation of a multiprotein signaling complex which has shown to be involved in
growth promoting effects[16].
EpCAM makes an ideal model system due to its ubiquity in carcinomas and
CTCs, apparent signaling role, and prognosis indication.

B.

Clinical Relevance of CTCs

CTCs are present in the bloodstream of patients with malignant epithelial tumors
at 50-300,000 cells/mL[4], but are quite rare compared to the number of mononuclear
cells in the same volume, only one per million or 10 million[9]. Early stage cancers are
expected to have far fewer CTCs, so detection of CTCs is very much a needle-in-thehaystack type problem. Furthermore, due to the heterogeneous nature typical of
malignant tumors, cancer types do not always display the same biomarkers. Cells from
within the same tumor may not even display the same biomarker profile, thus there is still
disagreement over the proper CTC testing methods and interpretation of the results[19],
[20].
Because they are rare events, enrichment protocols can be employed to increase
the concentration of CTCs, but at the risk of sample loss during the enrichment[20].
Micro and nanotechnologies are under development to provide CTC enrichment with low
sample loss[21–26]. It is likely that micro and nanotechnology applications in this area
will advance alongside detection applications.
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C.

Molecular Recognition

Specific molecular interactions are necessary for the elaborate organization of our
bodies. Cells display surface markers and receptors with precisely defined structures that
contain recognition sequences. Complementary sequences exist on other molecules, such
as growth factors or markers displayed on other cells, which are only complementary to
that molecule and may bind specifically to it with a force proportional to the change in
enthalpy, minimizing the free energy[27]. Binding events can and usually do set off
signaling cascades, enabling cells to interact with each other and the environment.
Biology has taken advantage of specific binding to investigate the properties and
behaviors of cells. Antibodies are raised to form a complementary sequence which binds
specifically to a region of a desired target molecule. Researchers can use antibodies
tagged with a dye, enzyme or other signal molecule to determine the presence of a
molecule of interest in cell, tissue or other samples. This sums up labeled detection.
Label-free detection attempts to circumvent the label by measuring intrinsic
properties of the binding event itself. This is where micro and nanotechnology come into
play. Structures fabricated on a nanometer or micrometer length scale are sensitive to
forces and signals in delicate biological systems which could never be observed at the
macroscale.
Stresses due to free energy change upon specific binding have been investigated
with microcantilever arrays [28–31]. One half of the binding pair, i.e. an ssDNA or
receptor, is attached to the surface of the microcantilever. When the complementary
ssDNA or ligand is introduced, the specific binding generates an expansive stress on the
8

cantilever surface causing it to deflect. The microcantilevers must be very soft to respond
to this small force, thus there is considerable cantilever motion due to the movement of
the fluid. Precise position measurement relative to a reference (unfunctionalized)
cantilever is required to detect the deflection due to binding which somewhat offsets the
label-free advantage of these sensors. Nonetheless, the microcantilever deflection
illustrates the power of nanotechnology to resolve biomolecular binding events.

Figure II.2 Specific binding causes microcantilever deflection, from [29].

D.

Carbon Nanotube Biosensors

Electrical sensing offers a more streamlined approach than measuring sub-nm
mechanical deflections. Carbon nanotubes, along with nanowires and recently graphene
[32] have been investigated as transduction elements for biosensing. Nanowires perform
reliably but their high resistance limits their resolution. Carbon nanotubes have much
lower resistance and are ideal transduction elements but variations in as-prepared
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nanotube products and their network behaviors have limited their ultimate sensing
performance.
1.

Carbon Nanotube Properties
Multi wall carbon nanotubes were discovered in 1991 [33], single wall carbon

nanotubes in 1993 [34]. With reports of their extraordinary electrical and mechanical
properties [35], biosensing applications for carbon nanotubes soon fell under
investigation. Single wall carbon nanotubes (SWNT) are one dimensional molecular
wires. They are capable of ballistic electron transport along their axis, with micron order
mean free paths. They can be metallic or semiconducting. Nanotube synthesis typically
produces a 1:2 metallic:semiconducting ratio. This transport property is dependent on the
angle of the carbon lattice with respect to the tube axis[36]. The semiconducting fraction
of SWNTs are p-type semiconductors. As such, holes are the primary charge carriers and
a negative gate voltage switches them on. They are also sensitive to mechanical strains,
tension attenuates their conductance[37].
Despite advances in the processing, manipulation, and orienting of carbon
nanotubes, it is not yet feasible to place continuous nanotubes in parallel between
terminals over extended distances (10s or 100s of µm). Covering areas of this scale
requires an interconnected carbon nanotube network. Conduction pathways are made up
of several nanotubes each (some semiconducting and some metallic). Resistance between
SWNTs in junctions of the networks are much higher than the resistance along the tube
axes and contribute significantly to the resistance of the thin film.
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2.

Functionalization
A necessary first step for biosensor development is the attachment of

biomolecules to the nanotube sidewalls. Reports of this emerged as early as 1999 when
streptavidin proteins were shown forming helical crystals around multi wall carbon
nanotubes[38]. Likewise antibodies and other targeting proteins nonspecifically adsorb
onto nanotube sidewalls, but tend to adsorb nonspecifically to surrounding surfaces as
well.
The use of linker molecules was developed to attain higher specificity of the
proteins for the nanotubes during the conjugation process. Molecules such as
pyrenebutanoic acids[39], streptavidin-biotin complex, and G proteins[40] have been
used to attach the antibodies to the nanotube sidewalls with more uniform orientation.
Further chemical functionalization after the antibody attachment is useful to block
any unoccupied nanotube sidewall areas. Sensors may be incubated in a detergent such as
Tween20, TritonX, sodium dodecyl sulfate and others. The hydrophobic region of the
detergent adsorbs onto the nanotube sidewall while the hydrophilic end repels proteins
away. This minimizes the contribution of nonspecific interactions to the signal.

3.

Sensing mechanisms
Carbon nanotube biosensors have been designed to detect DNA[41–45],

glucose[43], [45–47], enzymes[45], [48], [49], protein-ligand interactions[50], and cancer
biomarkers[51–55]. Regarding cancer biomarkers, carbon nanotube biosensors have, to
this point, mainly been developed for free proteins whose elevated levels in blood serum
11

also indicate cancer. Prostate specific antigen (PSA) is a model system for this type of
detection. Detection limits of these sensors and others are shown in Table II.1.

Table II.1 Comparison of selected biosensors

Sensor type

Target

Detection Limit

Sample Volume

ssDNA

40 ng/mL (3µM) [30]

100 µL

PSA

0.2 ng/mL [29]

-

PSA

100 pM [51]

-

PSA

1 ng/mL [52]

5.0 µL

IgG

1 pg/mL [53]

10 µL

EpCAM

1 pM [56]

100 µm2

Microcantilever

Aligned CNT Thin
Film, Quartz substrate

CNT Thin Film

Magnetic Nanosensor

Typical electrical measurements from the biosensors are given as device
conductance (G) plotted vs. time and normalized to the initial device conductance (G0). A
class of CNT thin film biosensors utilize the Schottky barrier formed at the nanotubemetal contact for biosensing [57], [58], but the devices in this work have insulated
electrodes which should avoid the Schottky barrier effects.
The prevalent sensing mechanism described for CNT biosensors is the gating
effect of the target proteins as they bind to the antibodies. Binding of the targets to the
antibodies brings them near the CNT [58], [59], within the debye length of the fluid.
Positively charged proteins switch off semiconducting p-type CNT, decreasing device
conductance [51], [53], [60], [61]. Negatively charged proteins switch on the CNTs,
12

increasing the conductance [52]. Also, for n-type semiconducting nanowires, positively
charged proteins were shown to switch them on and increase conductance [61].
Reports of free EpCAM detection by CNT biosensors have not been found in the
literature, but EpCAM detection was included in a multiplexed magnetic nanosensor [56]
(included in Table II.1).
Human cells present a more complicated target than a protein, DNA, or other
biomolecule whose charge is a function of the solution pH. The cell surface contains
transport channels which pump ions in and out of the cell to maintain a membrane
potential. For epithelial cells, the membrane potential is typically 10-50 mV. There are
also many other surface markers present, aside from the specifice target, EpCAM, which
could interfere with the specific antibody-antigen interactions.
Electrical identification of cells by their specific binding to their surface markers
is also relatively unexplored. A prominent paper by Ning Shao et al. [54] is one of the
few to report specific electrical detection of epithelial cells by antibody-conjugated
carbon nanotubes. Sensors were constructed with just a few SWNT spanning a small 1
µm gap. Antibodies for breast cancer biomarkers Her2 or IGF1R were attached to the
nanotubes via a 1 pyrenebutanoic acid, succinimidyl ester linker molecule. The devices
were exposed to an excess of breast cancer cells, lines MCF7 and BT474 which
overexpress IGF1R and Her2 respectively. For specific pairings, the normalized
conductance, G/G0 dropped to ~0.2. The attenuation was attributed to tensional and
torsional strain generated by specific binding. The nanotubes were immobilized on each
end by the electrodes, and specific binding of the cell strained the nanotubes against the
13

immobilization points. The authors predicted that similar effects would not be observed
in an interconnected network (thin film) where nanotubes were not immobilized, but free
to move independently.
A

B

Figure II.3 (A)SWNT span 1 µm electrode gap, and (B) conductance attenuation for specific binding,
from [54].

Unfortunately, larger area sensors will be needed to detect cancer cells at
clinically relevant concentrations and sample volumes. The goal of this study was to
develop a thin film CNT biosensor capable of detecting EpCAM surface markers in cells.
The remainder of this thesis covers the steps taken to achieve this goal. EpCAM (MCF-7)
positive and EpCAM negative (MCF-10A) cell lines were cultured. Sensors were
designed and fabricated, using thin films tailored to improve sensing performance.
Antibody functionalization and testing protocols were designed to minimize signal
disturbances. EpCAM positive (MCF-7) and EpCAM negative (MCF-10A) cell lines
were tested with the sensor and distinct signals for the two lines were analyzed and
discussed.
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III.

METHODS

A.

Cell Culture

The MCF-7 cell line was used to simulate a circulating tumor cell. MCF-7 is a
breast adenocarcinoma line which overexpresses EpCAM. The MCF-10A cell line was
used as a control for the experiment. MCF-10A is a non-tumorigenic breast epithelial line
with no EpCAM expression [62]. Cryogenically frozen vials of both cell lines were
obtained from ATCC (item numbers HTB-22 and CRL-10317 for MCF-7 and MCF-10A
respectively).
Culture media for MCF7 was EMEM (ATCC #30-2003) with 10% fetal bovine
serum (FBS) (Cellgro #35-010-CV), 0.01 mg/mL human recombinant insulin (Sigma
#I9278), and 10 nM β-estradiol (Sigma #E2758). Culture media for MCF-10A was
MEBM (Lonza #CC-3150), minus the included GA-1000 growth supplement, plus 100
ng/mL cholera toxin (Sigma #C8052).
Confocal microscopy was used to confirm that EpCAM was present on MCF7
and absent on MCF-10A. Cells were grown on class coverslips, then fixed in
formaldehyde for 20 minutes. They were stained with primary antibody solution (2
µg/mL, mouse monoclonal anti-EpCAM, EMD #OP187) for 30 minutes at 37°C, then

15

stained in secondary antibody (1:250 dilution of Dylight 488 conjugated goat-anti-mouse,
Abcam #ab986789). Finally a DAPI nucleus stain was applied for 5 minutes at room
temperature. Coverslips were rinsed again and mounted on glass slides with SlowFade
Gold reagent.
MCF-10A

MCF-7

16

Figure III.1 Confocal microscopy of MCF7 (left) and MCF10A (right) cell lines. Green channel is
anti-EpCAM stain. 60x magnification, 50 µm scale bar.

For testing, cells were grown to high confluency, then detached using Accutase
solution (Sigma #A6964). Accutase was used in lieu of trypsin in an attempt to preserve
the surface markers on the cells so that the antibodies functionalized onto the device
could specifically recognize them. The cells were then centrifuged for 5 minutes at 220 g
and resuspended in PBS at 10,000 cells/µL. Cells suspended at this high concentration
were directly pipetted onto the devices to conduct the tests.

17

Jurkat E6-1 cells (purchased from ATCC, #TIB-152), CD4+ lymphoblasts, were
also used as control samples. They were cultured in RPMI-1640 media (ATCC #302001) supplemented with 10% FBS (Cellgro #35-010-CV).

B.

Carbon Nanotube Sensor Fabrication

The sensors are a simple two-terminal design. A carbon nanotube network
connects two Cr/Au electrodes and the electrodes are covered by an insulating layer of
SU8 photopolymer.

Figure III.2 Top down view of sensor showing SWNT thin film element and SU8 insulating layer

The first step in the process is assembling the nanotube network. A 99% weight,
CCVD synthesized, single wall/double wall carbon nanotube mixture was purchased
from Cheap Tubes Inc. Nanotubes are listed at 1-2 nm outer diameter and 3-30 µm
length. Nanotubes were suspended in IPA at 45 µg/mL and sonicated for 90 min. The
18

solution was then diluted to 3.5 µg/mL and sonicated for 3 hours to completely disperse
the nanotubes.
15 mL of the suspension was then further diluted with 85 mL of IPA before
vacuum filtration over a cellulose membrane, 0.22 µm pore size. This method selfregulates the deposition rate of nanotubes on the membrane to produce an evenly
distributed network [63]. The network is then pressed onto an oxidized (400 nm
thickness) silicon wafer for 30 minutes. Next the wafer is transferred to an acetone vapor
bath which dissolves the membrane.
The targeted thin film density was <5 CNT/µm, while still producing stable and
reproducible devices. Very thin films exposed more nanotube sidewalls and reduced the
number of junctions per nanotube so that nanotube resistance was more significant
relative to the junction resistance. Both of these attributes improved the sensing
properties of the film. SEM images were surveyed to determine the film density (Figure
III.3). Counting nanotube intersections with a grid of 1 µm lines superimposed on the
image yielded a mean density of 3.93 CNT/µm. The distribution of the nanotubes was
favorable as well. The standard deviation was 3.22, therefore over 68% of the film area is
favorable for sensing, containing 1-8 CNT/µm. See appendix for additional distribution
data.
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A

(C)

(B)

Figure III.3 Carbon nanotube thin film characterization. (a, previous page) SEM image. (b) AFM
topography image. (c) Histogram of thin film density obtained by counting the number of nanotubes
intersecting each element in an array of 1 µm lines superimposed on the SEM image in (a).

Patterning of the nanotube film and electrode and insulating layer fabrication are
done by photolithography in the cleanroom. Photomasks for these steps were designed by
Ms. Vanessa Velasco. AZ4620 photoresist is used to mask the nanotube film areas
needed for the sensor elements. Exposed nanotubes are etched away in a March reactive
ion etcher for 90 s at 200 W power and 10% O2. SC1827 photoresist is used to mask the
20

electrode pattern. Electrodes consist of a 10 nm Ni adhesion layer and a 90 nm Au layer.
They are deposited by sputtering in a Leskar PVD 75 system, 300 W DC power. Lastly,
the sensors are covered with SU8-2005, a 5 µm thick photopolymer layer. A window
over each of the nanotube sensor elements is developed but the electrodes remain
insulated beneath the SU8.

Figure III.4 Cut-away view of the device, not to scale.

C.

Carbon Nanotube Functionalization

Finished carbon nanotube sensors were functionalized with anti-EpCAM by a
pyrene linker molecule. The pyrene rings of 1-Pyrenebutanoic acid, succinimidyl ester
(PASE) adsorb onto carbon nanotube sidewalls by π-stacking. The ester on the other end
of the molecule provides an attachment point for antibodies. PASE (AnaSpec, #81238)
was dissolved in methanol at 1 mg/mL. Devices were incubated in the PASE solution for
1 hour at room temperature, then rinsed with methanol and water. Devices were then
incubated in anti-EpCAM (10 µg/mL in PBS, EMD Bioscience, #OP187) for 1 hour at
37°C. Lastly, a surfactant, Tween20, was used to block unfunctionalized nanotube
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sidewalls or PASE sites in order to minimize nonspecific interactions. Devices were
incubated in 0.5% Tween20 for 2 hours at room temperature. After incubation, devices
were washed with water, then each incubated in a 2 µL droplet of PBS overnight in a
humid chamber before testing.

Figure III.5 Sensors, 6 per chip, incubating in Tween20 droplets in a humid chamber.

Figure III.6 PASE-mab functionalized nanotube film (top) and bare film (bottom). Minimum
measured height is 5nm for the functionalized film and 3nm for the bare film.
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D.

Testing Protocol

The exact test protocol was revised throughout the course of the study as more
was learned about the characteristics of the sensors, but the instrumentation set-up and
many parameters remained constant.
Devices were placed on a Signatone probe station and the probe tips contacted the
device at the source and drain terminals (Figure III.7). These were wired to an Agilent
4156C Semiconductor Parameter Analyzer which was controlled via a custom LabVIEW
interface, developed by Mr. Tommy Roussel, running on a windows PC. A 100 mV bias
was applied and the source drain current, ISD, was recorded for the duration of the test.
Test solutions and samples were pipetted directly onto the device. In some cases
the test was initiated with the device already hydrated and samples were pipetted into this
droplet. The final testing protocol started with the device hydrated in a 2 µL droplet
which was placed immediately after functionalization and left overnight. The bias was
applied, and then a 5 µL droplet, either of cell suspension, PBS or water, was pipetted
directly into the standing 2 µL droplet. To compare results among devices, ISD data were
normalized to obtain the G/G0 signal.
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Figure III.7 Device during testing

The sensor element was also viewed an optical microscope to confirm the
presence of cells (Figure III.8). A concentration of 10,000 cells/µL consistently covered
the sensor element with 20-30 cells. Multiple MCF-7 and MCF-10A samples were tested
at each session, along with blank PBS and DI water samples.

Figure III.8 MCF-10A cells after being pipetted onto the sensor
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IV.

RESULTS AND DISCUSSION

A.

Sensor Development

Sensor reliability is one of the primary barriers to mainline adoption of carbon
nanotube biosensors. The first tests carried out using these devices were done in a similar
manner to the protocols reported for much smaller biosensors. The sensor, dry and
exposed to air, was probed and a 100 mV bias applied for 300 seconds. At 30 seconds, a
sample of cells suspended in PBS was pipetted onto the device. Wetting the sensor with
the buffer attenuated the current as expected. Unfortunately, this attenuation was very
inconsistent from device to device. About one in ten devices also underwent a steady
increase, then decrease in current. Thus any signals arising due to specific binding were
masked by the sudden and drastic change in the sensor environment. Many repetitions
failed to generate a discernible pattern, or a characteristic difference between the specific
and nonspecific binding signatures.
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Figure IV.1 Inconsistent readings upon sample introduction to dry sensors

Placing a PBS droplet on the device before or after applying the VDS bias
removed the initial-hydration current attenuation from the sample interaction signal.
However, noisy and anomalous readings persisted upon addition of the cell samples.
Reproducible signals remained impossible to obtain.
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Figure IV.2 Noise associated with sample testing persists when loading after a PBS droplet

Attempting to avoid the noise associated with the liquid sample introduction, a
study was conducted over extended time intervals. Cell samples at a concentration of
10,000 cells/µL were added to the devices and placed incubated at 37°C. A current
measurement was taken at 2 hours, 4 hours and 8 hours. Then the cells were fixed in
methanol, incubated in PBS overnight, and another reading was taken the next day. There
was no statistically significant difference between the MCF7 and MCF-10A samples. But
the pattern which emerged saw the current in all devices increase slightly up to the 4 hour
time point, then decrease at the 8 hour and post fixation time points to below the initial
value. This indicated that incubation in aqueous solutions alone was altering the nanotube
conductance.
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Figure IV.3 Conductance evolution in devices during incubation in PBS-cell suspension. G0 was the
conductance of the device prior to addition of the cells.

Tests on bare, unfunctionalized carbon nanotube devices revealed that extended
incubation in water resulted in decreased conductivity of the device. Furthermore, device
conductance gradually increased as they were exposed to air following fabrication. This
effect was reversed by storing the fabricated sensors in a vacuum chamber.
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Figure IV.4 Device conductance changes for air and water exposure.

Altogether these findings indicate that gas molecules were reversibly doping the
carbon nanotubes; Carbon nanotubes can be extremely sensitive to these effects [64]. The
effect accumulated as they were exposed to air, and was reversed for vacuum and liquid
environments. When in these environments, high concentrations of gas molecules in the
vicinity of the nanotubes would either be drawn out into the vacuum or dissolved into the
liquid. It was the reversing of the doping effects which lead to erratic behavior of the
sensor.
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Table IV.1 Effects on carbon nanotube conductance

Environment

Effect on Device current

Aqueous: Water/PBS

Decrease

Air

Increase

Vacuum

Decrease

Therefore, a fabrication and functionalization protocol was developed (as
described in Section III) which eliminates long term exposure and minimizes the
nanotubes total exposure to air as soon as the cleanroom fabrication steps are complete.
The photolithography processing should result in consistent levels of CNT doping among
sensors upon fabrication completion, so it was assumed that t=0 for air exposure at the
moment the last photolithography step is complete.
Devices constructed with this minimal air exposure method produced much more
consistent responses to blank PBS solutions for one hour (Figure IV.5). Additional PBS
droplets had to be added to prevent the devices from drying out during the test. The
humid chamber could not interface with the probe station so the devices were exposed to
the dry room air. Bare and functionalized devices both exhibited similar curve shapes, a
sharp drop in current followed by gradual recovery. However the functionalized device
current gradually declined over the interval unlike the bare devices.
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Figure IV.5 Consistent response to PBS addition for bare and functionalized devices

Consistent performing devices provided a stable platform to investigate the
specific binding signature, although one small issue remains unresolved. When the bias is
applied, some device currents drift upwards, some downwards, and some are steady. All
three examples are shown in Figure IV.5 (b). It is unclear what effect, if any, this has on
device sensitivity.
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B.

Specific Signature Identification

Elimination of noise due to gaseous doping enabled clear identification of the
specific vs. nonspecific binding signatures. There was still variation during the first
approximately 3 seconds of testing, but the devices soon reached a steady state value. For
this reason the signals were normalized to the steady state value rather than the initial
value. 9 devices were tested, 4 MCF-7, 4 MCF-10A, and 1 PBS control. The MCF-10A
signals all had the characteristic shape for plain PBS addition as established previously.
The PBS control reproduced this shape as well.
For the MCF-7 samples, 3 of the 4 exhibited an inverse shape while 1 had the
nonspecific shape.

Figure IV.6 Specific vs. nonspecific cellular recognition signals. Signals are normalized to their
steady state value before sample addition. They are plotted spaced apart for clarity.
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To determine the statistical significance of this result, the average slope of the 0.4
seconds immediately following the prominent inflection point was calculated for each
signal. Both data sets were determined to be random and of equal variance (appendix),
therefore a two-sample t-test was used.
Table IV.2 t-test results

MCF-7

MCF10-A

-0.1469

0.162

-0.0668

0.238

-0.0601

0.0726

0.0395

0.0291

Average

-0.0586

0.1254

Std. Deviation

0.0764

0.0932

Calculated Slopes

t statistic

-3.05326

Critical

+/-2.47015

p value

0.02352

The p value of 0.024 < 0.05 denotes that there is a significant difference between
the sampled MCF-7 signals and MCF-10A signals. This shows that the sensor is capable
of differentiating between two cell populations which are very similar except for their
surface markers, the first such accomplishment for a carbon nanotube-entangled network
electrical sensor. Surface marker mediated cellular identification is the basis for detection
of circulating tumor cells moving forward.
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Figure IV.7 MCF-7 and MCF-10A cells placed on sensors with non-functionalized CNT films.
Curves were similar to those for nonspecific interaction with the functionalized sensors and there
was no statistical difference between the two cell types.

To test whether the different readings were due to a difference between the two
cell types, rather than the presence or absence of EpCAM, the same tests were done using
non-functionalized nanotube films (Figure IV.7). With one exception, the characteristic
nonspecific signal was recorded all tests, and there was not a statistical difference
between the two cell types when comparing the slope following the signal maximum or
minimum, as was done for the functionalized sensor tests (Appendix).
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Figure IV.8 Jurkat E6-1 cell testing with functionalized and non-functionalized devices.

Additional controls were done with the Jurkat E6-1 cells, CD4+ lymphoblasts.
This cell line was selected because it certainly does not express EpCAM since it is not an
epithelial cell (MCF-10A may still express very low levels of EpCAM). Tests with the
Jurkats were inconclusive however. With the functionalized sensors, fluctuating signals
were observed following sample addition but non-functionalized sensors produced more
typical nonspecific signals.
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C.
1.

Interpretation

Epithelial Cell Lines
The MCF7 and MCF10A cell lines, like most mammalian non-excitable cells

have a negative resting potential. The potential is maintained by active transport of ions,
mainly sodium and potassium, across the membrane in order to facilitate transport of
other chemical species. MCF7 potential was reported to vary from -58.6 mV to -2.7 mV
with the cell cycle[65]. MCF10A membrane potential is estimated to be about -10 mV
[66] but a similar report correlated to the cell cycle is not available.
As MCF7 cells reached the sensor and EpCAM units bound to the anti-EpCAM
of the sensor, the sharp increase in conductance suggested an initial gating effect where
the negatively charged MCF7s switched on the p-type semiconducting nanotubes. The
sensor current then began to gradually return to near its initial value, either due to a loss
of charge by the cell or current leakage through the antibody-PASE linkage binding the
cell to the antibodies. The cell cycle dependent membrane potential of the MCF7 may
also have caused the signal to vary among tests based on the net membrane potential of
the 20-30 cells interfacing with the device for a given experiment.
Introduction of MCF10A to the device produced an opposite shaped curve, of the
same shape as for blank PBS addition, supporting the hypothesis that specific interaction
is required for the cell to affect the device. The cause of the shape of the curve produced
by the nonspecific MCF10A samples and blank PBS with no interaction is uncertain.
Perhaps it was due in part to the agitation of the fluid upon pipetting.
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A thorough comparison of the membrane potentials of the MCF7 and MCF10A
lines would strongly confirm these findings, if the two line are found to have equivalent
membrane potentials. It is difficult to assume so because tumorigenisis and cell cycle
deregulation are often closely linked [67], [68] and if the MCF7 cell cycle is sufficiently
deviated from the MCF10A, it could result in the two cell populations having different
membrane potential distributions.
The lack of a statistical difference between the two cell types in the control tests
with the non-functionalized sensors does show that the results for functionalized sensors
are not solely due to a difference in membrane potentials or other physical properties of
the two cell lines.

2.

Jurkat Cell Line
Testing with the Jurkat cells produced fluctuating signals where the characteristic

nonspecific signal was expected. A possible explanation for this is that the Jurkat cells
were responding to the non-human (mouse) IgG of the functionalized devices. This
would initiate calcium-mediated potassium channel activation [69] and the flux of ions
could be responsible for the signals observed. Additional tests would be needed to
determine whether this effect is indeed occurring. It will also be an important
consideration moving forward, to neutralize any immune response to the device
antibodies if present, because patient samples are likely to contain leukocytes.
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V.

CONCLUSIONS

A.

Summary

This study shows, for the first time, sensing of cellular EpCAM by a thin film
carbon nanotube device. The sensing is performed entirely on a simple two terminal
device with no moving parts. Such simplicity would enable this type of device to readily
be integrated with other micro/nano components for biotechnology. It is possible to
envision these types of sensors in many applications: Remote areas or those without hightech infrastructure, home use for patients who need to regularly monitor CTC counts or
other levels, and even perhaps in implantable devices, wirelessly relaying real time data
to physicians and care providers.
Development of the sensor throughout this study encountered and overcame many
pitfalls, most notably the gas adsorption and desorption effects. The steps needed to
control these errors were very simple. Minimizing device exposure to air and keeping the
device constantly hydrated from the end of the biofunctionalization process to the
initiation of testing transformed erratic unpredictable sensors into reliably performing
ones. Further investigation is sure to find other ways to remove environmental
disturbances and improve the device sensing capability
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Identifying cells by their membrane potential and electrical properties could
potentially push label-free detection inside the cell. Binding of cell surface proteins
typically initiates signaling cascades, phosphorylating and cleaving molecules inside the
cell. If these events could be transduced through a bound antibody-carbon nanotube
array, it would give great insight into the oft shrouded inner workings of the cell.

B.

Future Work

In order to focus on the specific binding signature, experiments were carried out
in near ideal conditions. Sensor surfaces were completely covered by both the test and
control cell lines. All tests were done with the cells suspended in PBS, with no other
proteins in solution that might compete for binding sites or otherwise alter the
experiment. Now that the specific cellular binding signature has been recorded, work can
be done to improve the signal and detect the cells under more physiological conditions,
alongside nonspecific cells and free proteins.
To move this technology forward, aspects of the device performance such as the
short initial drift in current, and interaction with leukocytes remain to be characterized.
Improvements can also be made to the device, including additional nanotube purification
steps to remove amorphous carbon and carbon nanoparticles [70], [71], annealing to
lower the metal contact resistance and desorb interfering molecules from the nanotube
sidewalls [72]. Sensors may also be cleaned with acid for re-use [58] which would be a
good test for reproducibility and to further isolate and characterize the specific signal.
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There are many exciting applications for this technology in the future, both near
and far. Continued development is sure to uncover more challenges, insights and
opportunities.
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APPENDIX

CNT Film density
V_npnts= 273; V_numNaNs= 0; V_numINFs= 0; V_avg= 3.93407;
V_Sum= 1074; V_sdev= 3.22947; V_sem= 0.195456; V_rms= 5.08607;
V_adev= 2.49213; V_skew= 1.23362; V_kurt= 1.70445; V_minloc= 6;
V_maxloc= 216; V_min= 0; V_max= 17; V_minRowLoc= 6;
V_minColLoc= 0; V_maxRowLoc= 8; V_maxColLoc= 16; V_startRow= 0;
V_endRow= 272;
CNT Film Lorentzian fit (Figure III.3)
Fit converged properly
fit_MegaWAve_Hist= W_coef[0]+W_coef[1]/((x-W_coef[2])^2+W_coef[3])
W_coef={-0.27186,389.49,2.2585,8.8351}
V_chisq= 221.487;V_npnts= 100;V_numNaNs= 0;V_numINFs= 0;
V_startRow= 0;V_endRow= 99;
W_sigma={0.169,28.9,0.0781,0.769}
Coefficient values ± one standard deviation
y0

=-0.27186 ± 0.169

A

=389.49 ± 28.9

x0

=2.2585 ± 0.0781

B

=8.8351 ± 0.769
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Statistical Analysis, Functionalized Sensors
Serial Randomness Test for root:wave3 (MCF7)
P>alpha so do not reject the hypothesis that the data are random.

Serial Randomness Test for root:wave4 (MCF10A)
P>alpha so do not reject the hypothesis that the data are random.
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F test for root:wave3 and root:wave4
F statistic inside the critical range => do not reject hypothesis of equal variances.
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T test for independent samples root:wave3 and root:wave4
Abs(t_statistic)>=Critical => there is significant difference between the populations
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Statistical Analysis, non-functionalized sensors
Data Sets
MCF10A

MCF7

0.0497192
0.0296412
0.00212742
-0.00961552

0.0362276
0.00990511
0.0239869
0.0442623

Serial Randomness Test for root:mcf10a_blank4slopes
P>alpha so do not reject the hypothesis that the data are random.
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Serial Randomness Test for root:mcf7_blank4slopes
P>alpha so do not reject the hypothesis that the data are random.

F test for root:mcf10a_blank4slopes and root:mcf7_blank4slopes
F statistic inside the critical range => do not reject hypothesis of equal variances.
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T test for independent samples root:mcf10a_blank4slopes and root:mcf7_blank4slopes
Abs(t_statistic)<Critical => there is no significant difference between the populations
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